Phase II study of CT-2103 as first- or second-line chemotherapy in patients with metastatic breast cancer: unexpected incidence of hypersensitivity reactions

Author： Lin Nancy   Parker Leroy   Come Steven   Burstein Harold   Haldoupis Margaret   Ryabin Nicole   Gelman Rebecca   Winer Eric   Shulman Lawrence  

Publisher： Springer Publishing Company

ISSN： 0167-6997

Source： Investigational New Drugs, Vol.25, Iss.4, 2007-08, pp. : 369-375

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Multicenter phase II study of S-1 monotherapy as second-line chemotherapy for advanced biliary tract cancer refractory to gemcitabine

By Sasaki Takashi  

Investigational New Drugs, Vol. 30, Iss. 2, 2012-04 ,pp. : 708-713

Springer Publishing Company

Access to resources Recommend Favorite

Vandetanib with docetaxel as second-line treatment for advanced breast cancer: a double-blind, placebo-controlled, randomized Phase II study

By Boér Katalin  

Investigational New Drugs, Vol. 30, Iss. 2, 2012-04 ,pp. : 681-687

Springer Publishing Company

Access to resources Recommend Favorite

Phase II study of oral S-1 with irinotecan and bevacizumab (SIRB) as first-line therapy for patients with metastatic colorectal cancer

By Yamada Yasuhide  

Investigational New Drugs, Vol. 30, Iss. 4, 2012-08 ,pp. : 1690-1696

Springer Publishing Company

Access to resources Recommend Favorite

Phase II trial of pemetrexed as second-line therapy in patients with metastatic urothelial carcinoma

By Galsky Matthew   Mironov Svetlana   Iasonos Alexia   Scattergood Joseph   Boyle Mary   Bajorin Dean  

Investigational New Drugs, Vol. 25, Iss. 3, 2007-06 ,pp. : 265-270

Springer Publishing Company

Access to resources Recommend Favorite

A phase II study of sabarubicin (MEN-10755) as second line therapy in patients with locally advanced or metastatic platinum/taxane resistant ovarian cancer

By Caponigro Francesco   Willemse Pax   Sorio Roberto   Floquet Anne   van Belle Simon   Demol Jan   Tambaro Rosa   Comandini Alessandro   Capriati Angela   Adank Sabine   Wanders Jantien  

Investigational New Drugs, Vol. 23, Iss. 1, 2005-01 ,pp. : 85-89

Springer Publishing Company

Access to resources Recommend Favorite